ABOUT 7th_NIF
> AGENDA
> REGISTRATION
> ATTENDEES
> PRESENTERS
> SPONSORS
> SUPPORTERS
> NETWORKING
> VENUE

> ABOUT LAST YEAR​

20-MINUTE PRESENTERs

​Actinogen Medical Ltd.
[ASX: ACW]

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.​

actinogen.com.au/

​AlgoTx

At AlgoTx we develop novel solutions to relieve patients with difficult-to-treat « Complex Pain ».

We do so by prioritizing indications that have no proven and approved therapy, and tailoring treatment to the very specific needs of the affected patients.

ATX01 is currently in Phase 2 clinical development in Chemotherapy-Induced Peripheral Neuropathy: The "ACT" study is in progress in the US and Europe. In addition, FDA and the German regulatory authority BfArM approved the initiation of a Phase 2 Proof-of-Concept study of ATX01 in a rare and painful disease, erythromelalgia ; The "EASE" study will start in Q2 2023 in the US and Germany.

ATX01’s topical administration enables the direct blockade of pain messaging in the nerve fibers of the skin, and limits the systemic side-effects potential associated with oral or intravenous drugs.

​algotx.com/

Cognition Therapeutics, Inc.
[​NASDAQ: CGTX]

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.

www.cogrx.com

HanAll Biopharma
[​KRX: 009420]

HanAll Biopharma is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for 50 years.

HanAll has also expanded its focus to ophthalmology, immunology, oncology, and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials worldwide for the treatment of autoimmune diseases, including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another key asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease.

www.hanall.com/

​IAMA Therapeutics S.r.l.

IAMA Therapeutics pushes the boundaries of neuroscience drug discovery to develop new therapeutic opportunities and make a difference in children affected by epilepsy, neurodevelopmental and cognitive disorders. IAMA Therapeutics is developing IAMA-6 for potentially treating drug-resistant epilepsies and rare syndromic forms of autism, in addition to chloride modulators targeting neuropsychiatric conditions characterized by cognitive impairment.

iamatherapeutics.com/

Minoryx Therapeutics

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

​www.minoryx.com/

Oryzon Genomics, S.A.

A public clinical-stage biopharma developing epigenetics for CNS disorders and Oncology. +50 highly-qualified professionals located in Barcelona, Boston, NYC and San Diego. Listed in Spain, aiming at NASDAQ-listing.
Two uncorrelated Phase II compounds: iadademstat (oncology) and vafidemstat (CNS).

Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML and solid tumors. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Two ongoing trials in R/RFlt3mut+ AML and, SCLC and preparing a new trial in SCLC.

Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor. Positive results reducing aggression in a Phase IIa basket trial in psychiatric patients. Two Phase IIb trials: One in borderline personality disorder fully recruited and the other in schizophrenia actively recruiting. Also launching a CNS personalized medicine program, starting with a Phase I/II trial in Kabuki syndrome.

www.oryzon.com/

Quince Therapeutics
[​NASDAQ: QNCX]

Quince Therapeutics is a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases. The company is actively seeking compelling clinical-stage assets available for in-licensing and acquisition to expand our development pipeline.

quincetx.com/

Synendos Therapeutics AG

Synendos is a new, dynamic neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric disorders. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first in class, NCEs that modulate the ECS through a self-limiting mode of action with the potential to deliver meaningful benefits to patients.

www.synendos.com/

Tonix Pharmaceuticals Holding Corp.

​Tonix is a biopharmaceutical company focused on bringing novel therapeutics and diagnostics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases.

​www.tonixpharma.com/

10-MINUTE PRESENTERS

EpiVario, Inc.

EpiVario is a preclinical stage biotechnology company that is developing neuroepigenetic modulators to treat memory related psychiatric disorders.

Our cofounders, Dr. Shelley Berger and Dr. Philipp Mews are leaders in the field of neuroepigenetics.
​
Recently, they published the discovery of a key metablic enzyme, ACSS2, which functions in the nucleus of neurons to activate genes as memories are established or reconsolidated after recall (Nature, 2017 & 2019).

epivario.com/

Kynexis Therapeutics

Kinoxis Therapeutics Pty Ltd (Kinoxis) is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney.  Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors. Kinoxis has also secured significant funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.

​Lys Therapeutics

Lys Therapeutics is a biotechnology company pioneering a breakthrough approach to treat patients suffering from neurodegenerative or neurovascular disorders. Its main drug is a first-in-class monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action.

lystherapeutics.com/

ProNeurogen, Inc.

ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, memory loss and dementia. ProNeurogen's novel drug technology is based on R&D conducted at the University of Arizona.

www.proneurogen.com/

Sinaptica Therapeutics

Sinaptica Therapeutics™ has developed a breakthrough personalized closed-loop neuromodulation
therapy for Alzheimer’s Disease that works by enhancing neuroplasticity via neurostimulation of key
brain networks involved in memory.

sinapticatx.com/

TikoMed AB

TIKOMED is a privately held company focused on development of ILB, a small molecule for neurological conditions, documented to phase 2 in ALS and with a MoA supporting several additional indication.

www.tikomed.com